Cargando…

Siponimod: A Review in Secondary Progressive Multiple Sclerosis

Oral siponimod (Mayzent(®)), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries. In the pivotal E...

Descripción completa

Detalles Bibliográficos
Autor principal: Scott, Lesley J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773609/
https://www.ncbi.nlm.nih.gov/pubmed/33108633
http://dx.doi.org/10.1007/s40263-020-00771-z
_version_ 1783630079575719936
author Scott, Lesley J.
author_facet Scott, Lesley J.
author_sort Scott, Lesley J.
collection PubMed
description Oral siponimod (Mayzent(®)), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries. In the pivotal EXPAND trial (median duration double-blind treatment 18 months) in a broad spectrum of patients with SPMS, once-daily oral siponimod 2 mg (initial dose titration over 6 days) was significantly more effective than placebo in reducing clinical and MRI-defined outcomes of disease activity and disability progression, including 3-month confirmed disability progression on the Expanded Disability Status Scale (EDSS), and was generally well tolerated in the core phase of the study. These beneficial effects of siponimod appeared to be sustained during up to 5 years of treatment in the ongoing open-label extension phase of EXPAND. The safety profile of siponimod is similar to that of other agents in its class, including adverse events of special interest (i.e. those known to be associated with S1PR modulators). No new safety signals were identified during up to 5 years’ treatment in the open-label extension phase. Albeit further long-term efficacy and safety data from the real-world setting are required to fully define its role, given the paucity of current treatment options and its convenient dosage regimen, siponimod represents an important emerging option for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging-features of inflammatory activity.
format Online
Article
Text
id pubmed-7773609
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77736092021-01-04 Siponimod: A Review in Secondary Progressive Multiple Sclerosis Scott, Lesley J. CNS Drugs Adis Drug Evaluation Oral siponimod (Mayzent(®)), a next-generation, selective sphingosine 1-phosphate receptor (S1PR) 1 and 5 modulator, is approved in several countries for the treatment of secondary progressive multiple sclerosis (SPMS), with specific indications varying between individual countries. In the pivotal EXPAND trial (median duration double-blind treatment 18 months) in a broad spectrum of patients with SPMS, once-daily oral siponimod 2 mg (initial dose titration over 6 days) was significantly more effective than placebo in reducing clinical and MRI-defined outcomes of disease activity and disability progression, including 3-month confirmed disability progression on the Expanded Disability Status Scale (EDSS), and was generally well tolerated in the core phase of the study. These beneficial effects of siponimod appeared to be sustained during up to 5 years of treatment in the ongoing open-label extension phase of EXPAND. The safety profile of siponimod is similar to that of other agents in its class, including adverse events of special interest (i.e. those known to be associated with S1PR modulators). No new safety signals were identified during up to 5 years’ treatment in the open-label extension phase. Albeit further long-term efficacy and safety data from the real-world setting are required to fully define its role, given the paucity of current treatment options and its convenient dosage regimen, siponimod represents an important emerging option for the treatment of adult patients with SPMS with active disease evidenced by relapses or imaging-features of inflammatory activity. Springer International Publishing 2020-10-27 2020 /pmc/articles/PMC7773609/ /pubmed/33108633 http://dx.doi.org/10.1007/s40263-020-00771-z Text en © Springer Nature Switzerland AG 2020, corrected publication 2020 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Adis Drug Evaluation
Scott, Lesley J.
Siponimod: A Review in Secondary Progressive Multiple Sclerosis
title Siponimod: A Review in Secondary Progressive Multiple Sclerosis
title_full Siponimod: A Review in Secondary Progressive Multiple Sclerosis
title_fullStr Siponimod: A Review in Secondary Progressive Multiple Sclerosis
title_full_unstemmed Siponimod: A Review in Secondary Progressive Multiple Sclerosis
title_short Siponimod: A Review in Secondary Progressive Multiple Sclerosis
title_sort siponimod: a review in secondary progressive multiple sclerosis
topic Adis Drug Evaluation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773609/
https://www.ncbi.nlm.nih.gov/pubmed/33108633
http://dx.doi.org/10.1007/s40263-020-00771-z
work_keys_str_mv AT scottlesleyj siponimodareviewinsecondaryprogressivemultiplesclerosis